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Edited by Beat ImhofAbstract Glycogen storage disease type Ia (GSD-Ia) patients
deﬁcient in glucose-6-phosphatase-a manifest a disturbed glucose
homeostasis. We hypothesized that disturbed glucose homeosta-
sis might aﬀect myeloid functions. Here, we show that GSD-Ia
mice exhibit normal neutrophil activities but have elevated mye-
loid progenitor cells in the bone marrow and spleen. Interest-
ingly, GSD-Ia mice exhibit a persistent increase in peripheral
blood neutrophil counts along with elevated serum levels of gran-
ulocyte colony stimulating factor and cytokine-induced neutro-
phil chemoattractant. Taken together, our results suggest that
a loss of glucose homeostasis can compromise the immune sys-
tem, resulting in neutrophilia. This may explain some of the
unexpected clinical manifestations seen in GSD-Ia.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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function1. Introduction
Glycogen storage disease type I (GSD-I) is caused by a deﬁ-
ciency in the glucose-6-phosphatase-a (G6Pase-a) complex
that consists of a glucose-6-phosphate transporter (G6PT) that
translocates glucose-6-phosphate (G6P) from the cytoplasm
into the lumen of the endoplasmic reticulum, and a G6Pase-
a catalytic subunit (also known as G6PC), that hydrolyses end-
oluminal G6P to glucose and phosphate [1]. Together, they
work to maintain blood glucose homeostasis between meals.
A deﬁciency of G6Pase-a causes GSD type Ia (GSD-Ia,
MIM232200) and a deﬁciency in G6PT causes GSD type Ib
(GSD-Ib, MIM232220) [1]. While G6Pase-a is expressed pri-
marily in the liver, kidney and intestine [2], G6PT is expressed
ubiquitously [3]. G6Pase-a and G6PT activities are function-
ally linked [4,5] and a detrimental mutation in either protein
prevents the other from functioning eﬃciently and leads to
the same metabolic phenotype, characterized by fasting hypo-
glycemia, hepatomegaly, nephromegaly, hyperlipidemia,
hyperuricemia, lactic acidemia, and growth retardation [1].*Corresponding author. Fax: +1 301 402 6035.
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are almost identical [1], GSD-Ib patients exhibit neutropenia
and myeloid dysfunctions [1,6,7]. There are no clinical reports
of neutrophil dysfunctions in GSD-Ia patients, and it has been
assumed that the GSD-Ib defects arise from alternative activ-
ities of G6PT in myeloid tissues. We suggest an alternative
hypothesis, namely that the loss of glucose homeostasis does
underlie the neutrophil defects, but that the dysfunctions in
GSD-Ia do not rise to the level of clinical observation or sig-
niﬁcance seen in GSD-Ib. In this report, we report evidence
to support our hypothesis.
To study the biology and pathophysiology of GSD-I, we
have generated G6Pase-a-deﬁcient [4] and G6PT-deﬁcient [8]
mouse strains that mimic the human disorders. Both manifest
the metabolic abnormalities characteristics of a disturbed
glucose homeostasis and the GSD-Ib mice also suﬀer from
neutropenia and neutrophil dysfunctions characteristic of
GSD-Ib. As with the human disease, serum levels of granulo-
cyte colony stimulating factor (G-CSF) and cytokine-induced
neutrophil chemoattractant (KC) are markedly increased in
GSD-Ib mice [8]. We also showed that G6PT expression in
bone marrow and neutrophils is required for normal myeloid
functions [9]. However, our study also suggests that some of
the myeloid abnormalities observed in GSD-Ib are caused by
the disturbed glucose homeostasis [9].
The similarity in metabolic abnormalities between GSD-Ia
and GSD-Ib prompted us to examine myeloid functions in
GSD-Ia mice. We show that the GSD-Ia neutrophils have a
normal respiratory burst, chemotaxis, and calcium ﬂux activi-
ties. Like GSD-Ib mice, bone and spleen of GSD-Ia mice are
developmentally delayed and both organs exhibit hypocellular-
ity and moderate increases in myeloid progenitor cell numbers.
Interestingly, serum levels of G-CSF and KC are also elevated
in GSD-Ia mice. In contrast to neutropenia manifested by
GSD-Ib patients and mice, peripheral blood neutrophil counts
are consistently elevated in GSD-Ia mice.2. Materials and methods
2.1. Respiratory burst, chemotaxis, and [Ca2+]i measurements
All animal studies were conducted under an animal protocol ap-
proved by the NICHD Animal Care and Use Committee. A glucose
therapy was administered to the GSD-Ia mice as described previously
[4] and mice that survived weaning were given unrestricted access to
Mouse Chow (Zeigler Bros., Inc., Gardners, PA). GSD-Ia is an auto-
somal recessive disorder [1]. Since the phenotypes of wild-type andEuropean Biochemical Societies.
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ment, metabolic functions and myeloid functions [4], we will use the
designation ‘‘unaﬀected’’ or ‘‘control’’ mice to refer to either wild-type
or heterozygous mice.
Neutrophils were isolated from thioglycollate-stimulated peritonea
of 6–7-week-old mice as described previously [8]. Neutrophils were
activated with 200 ng/ml of phorbol myristate acetate (PMA; Sigma
Chemical Co.) and neutrophil respiratory burst was monitored by
luminal-ampliﬁed chemiluminescence using the LumiMax Superoxide
Anion Detection kit (Stratagene, La Jolla, CA) as described previously
[8].
Neutrophil chemotaxis in response to f-Met-Leu-Phe (fMLP, Sigma
Chemical Co.), KC, or macrophage inﬂammatory protein-2 (MIP-2)
(PeproTech Inc., Rocky Hill, NJ) was performed in 48-well chambers
(NeuroProbe, Gaithersburg, MD) using polyvinylpyrrolidone-free
polycarbonate membranes with 3 lm pores as described previously
[8]. Cells were counted in six randomly selected ﬁelds at 400-fold mag-
niﬁcation and reported as the mean average.
Intracellular calcium ion concentration measurements ([Ca2+]i) in
neutrophils were performed in poly-L-lysine coated 96-well plates
(Greiner, Longwood, FL). The neutrophils (106 cells) were suspended
in 100 ll of 1· HBSS containing 10 mM HEPES and followed by
100 ll of FLIPER calcium 3 assay kit component A (Molecular De-
vices, Sunnyvale, CA) dissolved in HEPEfS–HBSS buﬀer. The plate
was then loaded into a Flexstation Fluorimeter (Molecular Devices)
set at 37 C, the appropriate ligands added to the plate robotically,
and cells were excited at 485 nm, and the ﬂuorescence intensities de-
tected and recorded every 0.5 s at 515 nm.2.2. Hematological and phenotype analyses
For the diﬀerential leukocyte counts, blood samples were collected
from the tail vein of mice using EDTA-containing CAPIJECT tubes
(TerumoMedical Co., Elkton, MD). Manual 200-cell leukocyte diﬀer-
ential counts of peripheral blood cells were performed on Hema 3
(Fisher Scientiﬁc, Pittsburgh, PA.) stained smears as described previ-
ously [8]. The cytokines, G-CSF and KC were quantiﬁed using Quan-
tikine ELISA kits (R& D Systems Inc., Minneapolis, MN). For
hematoxylin and eosin (H&E) staining, tissues were preserved in
10% neutral buﬀered formalin, embedded in paraﬃn, and sectioned
at 4–6 lm thickness.2.3. Hematopoietic progenitor cell assays
Progenitor cells were assayed in semisolid agar cultures by plating
2 · 104 bone marrow or 105 spleen cells in 1 ml of methylcellulose med-
ia (MethoCult M3231, Stem Cell Technologies, Vancouver, Canada)
supplemented with G-CSF (10 ng/ml), granulocyte macrophage-CSF
(GM-CSF) (10 ng/ml), or macrophage-CSF (M-CSF) (2.5 ng/ml).
The number of colonies containing more than 50 cells was counted
on days 7–9.2.4. Statistical analysis
The unpaired t test was performed using the GraphPad Prism Pro-
gram, version 4 (GraphPad Software, San Diego, CA). Values were
considered statistically signiﬁcant at P < 0.05.3. Results
3.1. The GSD-Ia mice do not manifest neutrophil dysfunctions
characteristics of GSD-Ib
Neutrophils from GSD-Ib patients [6,7] and mice [8] exhibit
impaired respiratory burst, chemotaxis, and calcium ﬂux activ-
ities. We therefore examined neutrophil activities in thioglycol-
late-recruited peritoneal neutrophils from GSD-Ia and their
unaﬀected littermates. Results in Fig. 1A show that after expo-
sure to PMA, superoxide production was markedly increased
in both control and GSD-Ia neutrophils and both activities re-
mained elevated for more than 16 min. Moreover, neutrophils
from control and GSD-Ia mice exhibited nearly identical dose-dependent chemotactic responses to fMLP, KC, and MIP-2
(Fig. 1B). In a similar fashion the thioglycollate-elicited perito-
neal neutrophils from control and GSD-Ia mice showed simi-
lar increases in Ca2+ mobilization in response to fMLP, KC,
and MIP-2 (Fig. 1C).3.2. Altered hematopoiesis in the bone marrow and spleen of
GSD-Ia mice
After birth, bone marrow is the primary site of maturation
and development of hematopoietic cells [10]. In neonatal mice,
the spleen is also a hematopoietic organ [11]. In GSD-Ib mice,
both the bone and spleen are developmentally delayed [8] and
the same is observed in the GSD-Ia mice (Fig. 2). In the unaf-
fected mice the epiphyses and growth plate of femoral and ti-
bia bones were well formed at 2 weeks of age (Fig. 2A), but in
GSD-Ia mice the epiphyses and growth plate were not evident
at 2 weeks of age becoming well formed only at 4–5 weeks of
age (Fig. 2A). Similarly, the white pulps in the spleen of the
unaﬀected mice are evident at 1 week of age and well formed
by 2 weeks of age (Fig. 2B), but in the GSD-Ia mice are not
evident until 3 weeks of age, becoming well formed only at 5
weeks of age (Fig. 2B).
We then examined colony-forming progenitor cells in the
bone marrows and spleens of 3-week-old GSD-Ia and control
littermates. In bone marrow aspirates combined from the fe-
mur and tibia, the total numbers of cells in the unaﬀected mice
are 3.3-fold higher than those in the GSD-Ia mice (Fig. 3A),
consistent with the delay in postnatal development. The colony
forming units (CFU) in bone marrow aspirates after in vitro
stimulation with G-CSF, GM-CSF, or M-CSF revealed 1.3-
fold more CFU-G, 1.7-fold more CFU-GM, and 1.4-fold more
CFU-M in GSD-Ia mice compared to the control littermates
(Fig. 3A). In 3-week-old GSD-Ib mice, the numbers of bone
marrow CFU-G, CFU-GM, and CFU-M were 3.7-, 10.5-,
and 3.9-fold higher, respectively than age-matched control
mice [8]. Therefore, the elevations in GSD-Ia mice are reminis-
cent of, though not as highly elevated as the numbers observed
in GSD-Ib mice [8].
The total numbers of cells in the spleen in 3-week-old control
mice were 3-fold higher than those in the GSD-Ia littermates
and the numbers of splenic CFU-G, CFU-GM, and CFU-M
in GSD-Ia mice were 4.7-, 5.5-, and 3.6-fold higher, respec-
tively than age-matched control mice (Fig. 3B). In 3-week-
old GSD-Ib mice, the numbers of splenic CFU-G, CFU-
GM, and CFU-M were similarly elevated, being 3.7-, 10.5-,
and 3.9-fold higher, respectively than age-matched control
mice [8].3.3. GSD-Ia mice exhibit neutrophilia along with increased
serum levels of G-CSF and KC
In GSD-Ib mice, serum levels of G-CSF and KC were
abnormally increased and G-CSF and KC in 3-week-old
GSD-Ib mice were 5.5- and 6.1-fold higher, respectively, than
the unaﬀected littermates [8]. In 3-week-old GSD-Ia mice, ser-
um G-CSF and KC values were also increased but only to 2-
and 3-fold higher, respectively, than the control animals
(Fig. 4A). Serum G-CSF and KC remained elevated being
1.7- and 3-fold higher, respectively, than the unaﬀected litter-
mates at age 6 weeks (Fig. 4A).
Diﬀerential peripheral blood leukocyte counts revealed that
neutrophil counts in 1-week-old GSD-Ia mice averaged 78% of
Fig. 1. GSD-Ia neutrophils exhibit no defect in respiratory burst, chemotaxis, and calcium ﬂux. Neutrophils were isolated from thioglycollate-
induced peritoneum of 6–7-week-old unaﬀected () and GSD-Ia () mice. (A) Neutrophil respiratory burst activity. Representative experiments are
shown. (B) Concentration-dependent chemotaxis in response to fMLP, KC or MIP-2. Values represent means ± S.E.M. of quadruplet
determinations. (C) Ca2+ ﬂux in response to 106 M of fMLP, KC or MIP-2. Representative experiments are shown.
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neutrophil counts in the unaﬀected mice increased slightly dur-
ing postnatal development, neutrophil counts in GSD-Ia mice
increased markedly with age (Fig. 4B). As a result, neutrophil
counts in 2-, 3-, and 6-week-old GSD-Ia mice averaged 1.2-,
1.7-, and 2.2-fold higher, respectively, than the counts in the
control littermates. On the other hand, blood lymphocyte,
monocyte, and eosinophil/basophil counts were similar be-
tween 6-week-old GSD-Ia and control mice (Fig. 4C). The
neutrophilia seen in GSD-Ia mice was a marked contrast to
the neutropenia manifested by GSD-Ib patients [6,7] and mice
[8] despite a higher increase in serum levels of G-CSF and KC
or interleukin-8 (IL-8) in GSD-Ib [8].4. Discussion
GSD-Ia and GSD-Ib share similar metabolic abnormalities
caused by the loss of interprandial glucose homeostasis [1].
However GSD-Ib patients and mice manifest additional symp-
toms of neutrophil dysfunctions. Since the G6PT gene has a
ubiquitous expression proﬁle [3] compared to the liver/kid-
ney/intestine restricted proﬁle of the G6Pase-a gene [2], it
has been assumed that the neutrophil dysfunctions reﬂect a
secondary activity of the G6PT protein in myeloid tissues.
While we have shown that there is good evidence for a second-
ary activity for G6PT, we have also hypothesized that disrup-
tion of glucose homeostasis could also contribute, in part, to
Fig. 2. Histological analyses of bone and spleen. The unaﬀected (+/+ and +/) and GSD-Ia (/) mice between 1 and 5 weeks of age were examined.
(A) H&E stained bone sections at magniﬁcations of ·50. (B) H&E stained spleen sections at magniﬁcations of ·50.
Fig. 3. Total cell counts and myeloid progenitor cells in the femur plus tibia and spleen of GSD-Ia mice. The myeloid functions were examined in 3-
week-old unaﬀected (+/+ and +/) and GSD-Ia (/) mice. CFU were determined following stimulation bone marrow or spleen cells with G-CSF,
GM-CSF, or M-CSF. Results are the mean ± SEM from four separate experiments in which each mouse was assessed individually. (A) Bone
marrow. (B) Spleen. *P < 0.05; **P < 0.005; ***P < 0.0001.
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Fig. 4. Analysis of serum levels of G-CSF and KC and peripheral blood leukocyte counts. The unaﬀected (+/+ and +/) and GSD-Ia (/) mice
between 1 and 6 weeks of age were examined. (A) Serum cytokines in mice at 3 weeks (n = 37 for +/+ and +/ and /) and 6 weeks (n = 12 for +/+
and +/ and n = 20 for /) of age. (B) Blood neutrophil counts in mice during post-natal development. *P < 0.05; **P < 0.005; ***P < 0.001. The
diﬀerences in neutrophil counts between control and GSD-Ia mice at 1 and 2 weeks of age are not statistically signiﬁcant. (C) Blood lymphocyte,
monocyte, and eosinophil/basophil counts in 6-week-old mice. The diﬀerences between control and GSD-Ia mice are not statistically signiﬁcant.
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activity should also diﬀer from the controls. Consistent with
our hypothesis, the GSD-Ia mice exhibit an elevated myeloid
progenitor cell frequency in the bone marrow and spleen,
and have increased serum concentrations of G-CSF and KC,
reminiscent of GSD-Ib [8]. Notably, these changes are signiﬁ-
cantly less pronounced in GSD-Ia than GSD-Ib mice. More
interestingly, while GSD-Ib patients and mice exhibit neutro-
penia, the GSD-Ia mice exhibit neutrophilia. Functionally,
the GSD-Ia mice exhibit no defects in neutrophil respiratory
burst, chemotaxis, or calcium ﬂux, indicating that G6Pase-a
expression is not required for normal neutrophil functions.
This is not unexpected because neutrophils do not express
the G6Pase-a gene [3]. Taken together, our study suggests that
myeloid functions in GSD-Ia are also abnormal, if not clini-
cally overt, and arise from the disturbance of glucose homeo-
stasis.
The neutrophil number in the blood is tightly regulated and
represents a balance between the production, release, and
clearance of neutrophils from the circulation. A key compo-
nent in this is G-CSF, a hematopoietic growth factor that reg-
ulates granulopoiesis [12,13]. KC, a member of the CXC
chemokine family, also modulates the neutrophil number, by
recruiting neutrophils to local sites of inﬂammation [14,15].
In this study, the serum levels of G-CSF and KC in GSD-Ia
mice were 2- and 3-fold higher, respectively than the levels in
the unaﬀected littermates, indicating an underlying challenge
to the immune system [14–16]. Consistent with studies thatcorrelate overexpression of G-CSF and IL-8, the human
homolog of KC, with neutrophilia [17,18]; we also observed
neutrophilia in GSD-Ia mice. The cause of the increase in cyto-
kines in GSD-Ia mice is unclear; however, since there is a long-
term damage to both the liver and kidney in GSD-Ia, despite
dietary controls, it is reasonable to suggest there is a progres-
sive low level of immune challenge reﬂected by these ﬁndings.
In this regard, it is interesting that the increased secretion of
chemokines has been detected in a wide variety of diseases,
including glomerulonephritis, ischemia-reperfusion, alcoholic
hepatitis, and hepatocellular carcinoma [14,15,19–21].
GSD-Ia [4] and GSD-Ib [8] mice are both growth retarded.
Likewise, bone and spleen are developmentally delayed in both
GSD-Ia (this study) and GSD-Ib [8] mice, and both are accom-
panied by reduced cellularity and increased myeloid progenitor
cell frequencies. When compared, the decrease in cellularity
and the increase in myeloid progenitor cells are more pro-
nounced in GSD-Ib mice, than the GSD-Ia mice, which corre-
lates with the serum levels of G-CSF and KC being elevated
more in GSD-Ib than GSD-Ia mice. Our current ﬁndings
therefore suggest that myeloid dysfunction in GSD-Ib could
be caused by the intrinsic G6PT deﬁciency in combination with
the disturbed glucose homeostasis.
The question remains why despite the marked increase in
serum G-CSF and IL-8 or KC in GSD-Ib patients and mice
[8] they manifest neutropenia. The explanation may lie in the
enhanced neutrophil apoptosis observed in GSD-Ib [22] which
is suﬃcient to counter the neutrophilia. G-CSF therapy has
3838 S.Y. Kim et al. / FEBS Letters 581 (2007) 3833–3838successfully treated neutropenia and the severity of infections
manifested by GSD-Ib patients [23]. However, G-CSF therapy
does not rescue neutrophil apoptosis in GSD-Ib patients [22].
Also, a normal number of functional neutrophils were required
for hematopoietic stem cell mobilization while neutropenic
phase impairs such mobilization [24]. This suggests that en-
hanced neutrophil apoptosis which cannot be rescued by G-
CSF therapy and the impairment in neutrophil-mediated
hematopoietic stem cell mobilization contribute to neutropenia
seen in GSD-Ib.
In summary, we have shown that a loss of glucose homeosta-
sis in GSD-I challenges the immune system leading to an in-
crease in serum G-CSF and KC. In GSD-Ia this leads to
neutrophilia. Our ﬁndings highlight the critical role blood glu-
cose homeostasis can play in normal myeloid function.
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